Faculty Collaboration Database

CTSI Cores Search Research Informatics REDCap

William H. Bradley MD

Professor

Institution: Medical College of Wisconsin
Department: Obstetrics and Gynecology
Division: Gynecologic Oncology
Program: Gynecological Oncology

Member of the Cancer Center

Send Message

Request Meeting

View Curriculum Vitae

Publications (63)

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. (Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A) Ann Oncol 2024 Nov;35(11):981-992 PMID: 39284381 PMCID: PMC11934258 SCOPUS ID: 2-s2.0-85204351787 09/17/2024 46 Citations

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer. (Uyar D, Michener CM, Bishop E, Hopp E, Simpson P, Zhang L, Rader JS, Rose PG, Mahdi HS, Debernardo R, Christian Q, Bradley W) Front Oncol 2024;14:1291090 PMID: 38410102 PMCID: PMC10894939 SCOPUS ID: 2-s2.0-85186485797 02/27/2024 1 Citation

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. (Mutch D, Voulgari A, Chen XM, Bradley WH, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraez AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y) Cancer 2024 Jun 01;130(11):1940-1951 PMID: 38288862 SCOPUS ID: 2-s2.0-85183847170 01/30/2024 2 Citations

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer (Uyar D, Michener CM, Bishop E, Hopp E, Simpson P, Zhang L, Rader JS, Rose PG, Mahdi HS, Debernardo R, Christian Q, Bradley W) Frontiers in Oncology 2024;14 SCOPUS ID: 2-s2.0-85186485797 01/01/2024 1 Citation

Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies. (McAlarnen LA, Small C, Tostrud L, Pan AY, Erickson B, Bedi M, Bradley WH) Brachytherapy 2023;22(5):630-639 PMID: 37394350 PMCID: PMC10757857 SCOPUS ID: 2-s2.0-85164349084 07/03/2023 3 Citations

Pathologic, immunologic, and clinical analysis of the microsatellite instability phenotype in endometrial carcinoma. (Mackinnon AC Jr, Johnson CM, Robin A, Christiansen L, Hanbazazh M, Summey RM, Chandrashaker D, Harada S, Bradley WH) Hum Pathol 2023 Sep;139:80-90 PMID: 37245630 SCOPUS ID: 2-s2.0-85167971699 05/29/2023 2 Citations

DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. (Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M) Gynecol Oncol 2023 May;172:82-91 PMID: 37001446 SCOPUS ID: 2-s2.0-85159042449 04/01/2023 17 Citations

Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. (Yin X, Davi R, Lamont EB, Thaker PH, Bradley WH, Leath CA 3rd, Moore KM, Anwer K, Musso L, Borys N) JCO Clin Cancer Inform 2023 Jan;7:e2200103 PMID: 36608308 SCOPUS ID: 2-s2.0-85145870315 01/07/2023 8 Citations

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor. (Summey RM, Rader JS, Moh M, Bradley W, Uyar D, Bishop E, McAlarnen L, Hopp E) Gynecol Oncol Rep 2022 Dec;44:101118 PMID: 36579182 PMCID: PMC9791298 SCOPUS ID: 2-s2.0-85144072474 12/30/2022 5 Citations

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor (Summey RM, Rader JS, Moh M, Bradley W, Uyar D, Bishop E, McAlarnen L, Hopp E) Gynecologic Oncology Reports December 2022;44 SCOPUS ID: 2-s2.0-85144072474 12/01/2022 5 Citations

Same-Day Discharge After Robotic Hysterectomy: A Resource Utilization and Quality Improvement Project. (McAlarnen LA, Maurer JE, Knaub A, Hopp E, Streitenberger K, Bishop E, Bradley W, Rader J, Uyar D) WMJ 2022 Oct;121(3):243-246 PMID: 36301654 SCOPUS ID: 2-s2.0-85140865266 10/28/2022 2 Citations

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. (DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN, SOLO1 Investigators) J Clin Oncol 2023 Jan 20;41(3):609-617 PMID: 36082969 PMCID: PMC9870219 SCOPUS ID: 2-s2.0-85146484599 09/10/2022 287 Citations

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study (O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A) Gynecologic Oncology July 2022;166(1):36-43 SCOPUS ID: 2-s2.0-85129973668 07/01/2022 22 Citations

Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14, 958. (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers (Basel) 2022 May 16;14(10) PMID: 35626175 PMCID: PMC9140135 SCOPUS ID: 2-s2.0-85129951244 05/29/2022 2 Citations

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. (O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A) Gynecol Oncol 2022 Jul;166(1):36-43 PMID: 35550709 PMCID: PMC10025898 SCOPUS ID: 2-s2.0-85129973668 05/14/2022 21 Citations

Correction to: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Cancers, (2022), 14, 958) (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers May-2 2022;14(10) SCOPUS ID: 2-s2.0-85129951244 05/01/2022 2 Citations

Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers (Basel) 2022 Feb 15;14(4) PMID: 35205706 PMCID: PMC8870411 SCOPUS ID: 2-s2.0-85124460063 02/26/2022 15 Citations

Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers February-2 2022;14(4) SCOPUS ID: 2-s2.0-85124460063 02/01/2022 15 Citations

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial (Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P) Lancet Oncology December 2021;22(12):1721-1731 SCOPUS ID: 2-s2.0-85120305618 12/01/2021 275 Citations

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. (Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P) Lancet Oncol 2021 Dec;22(12):1721-1731 PMID: 34715071 SCOPUS ID: 2-s2.0-85120305618 10/30/2021 273 Citations

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial (Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) Gynecologic Oncology October 2021;163(1):41-49 SCOPUS ID: 2-s2.0-85111728009 10/01/2021 29 Citations

Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. (Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, von Gruenigen VE) Gynecol Oncol 2021 Nov;163(2):392-397 PMID: 34548162 PMCID: PMC8805698 SCOPUS ID: 2-s2.0-85115193619 09/23/2021

Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352 PMID: 34380633 PMCID: PMC8530981 SCOPUS ID: 2-s2.0-85116424540 08/13/2021 42 Citations

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. (Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) Gynecol Oncol 2021 Oct;163(1):41-49 PMID: 34353615 PMCID: PMC9555119 SCOPUS ID: 2-s2.0-85111728009 08/07/2021 29 Citations

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. (Thaker PH, Bradley WH, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD) Clin Cancer Res 2021 Oct 15;27(20):5536-5545 PMID: 34326131 PMCID: PMC9338778 SCOPUS ID: 2-s2.0-85117384884 07/31/2021 20 Citations

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. (Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P) Lancet Oncol 2021 May;22(5):632-642 PMID: 33862001 SCOPUS ID: 2-s2.0-85105832067 04/17/2021 48 Citations

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators) Lancet Oncol 2021 May;22(5):609-619 PMID: 33845034 SCOPUS ID: 2-s2.0-85106068426 04/13/2021 302 Citations

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. (DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN) J Clin Oncol 2020 Oct 20;38(30):3528-3537 PMID: 32749942 PMCID: PMC8190876 SCOPUS ID: 2-s2.0-85093538492 08/05/2020 83 Citations

ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. (Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, Bradley W, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S) Oncogene 2020 Apr;39(14):2921-2933 PMID: 32029900 PMCID: PMC7346970 SCOPUS ID: 2-s2.0-85079196544 02/08/2020 34 Citations

Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer (González-Martín A, Pothuri B, Vergote I, Christensen RDP, Graybill W, Mirza MR, Mccormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ) Obstetrical and Gynecological Survey 1 January 2020;75(1):29-31 SCOPUS ID: 2-s2.0-85079048879 01/01/2020 2 Citations

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators) N Engl J Med 2019 Dec 19;381(25):2391-2402 PMID: 31562799 SCOPUS ID: 2-s2.0-85074763578 09/29/2019 1697 Citations

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. (Cara Amanda Mathews, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Sergeevna Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Susana N. Banerjee, Amit M. Oza, Antonio González-Martín, Carol Aghajanian, William Hampton Bradley, Elizabeth S. Lowe, Ralph Bloomfield, Paul Disilvestro) Journal of Clinical Oncology DOI: 10.1200/JCO.2019.37.15_suppl.5541 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 5541-5541. 05/20/2019

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. (Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators) Lancet Oncol 2019 Jun;20(6):862-876 PMID: 31076365 SCOPUS ID: 2-s2.0-85066276936 05/12/2019 78 Citations

Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer (Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, Disilvestro P) Obstetrical and Gynecological Survey 1 February 2019;74(2):86-87 SCOPUS ID: 2-s2.0-85061206932 02/01/2019 2 Citations

Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. (Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH) Int J Gynecol Cancer 2019 Jan;29(1):53-59 PMID: 30640684 SCOPUS ID: 2-s2.0-85060023480 01/15/2019 7 Citations

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. (Harold JA, Free SC, Bradley WH) Gynecol Oncol Rep 2018 Nov;26:91-93 PMID: 30426062 PMCID: PMC6223187 SCOPUS ID: 2-s2.0-85055867102 11/15/2018 4 Citations

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial (Friedlander M, Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza AM, González-Martín A, Aghajanian C, Bradley W, Lowe ES, Bloomfield R, Disilvestro P) Annals of Oncology November 2018;29:ix174-ix175 SCOPUS ID: 2-s2.0-85081599978 11/01/2018

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) N Engl J Med 2018 Dec 27;379(26):2495-2505 PMID: 30345884 SCOPUS ID: 2-s2.0-85058486553 10/23/2018 2168 Citations

Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. (von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L) Gynecol Oncol 2018 Jul;150(1):119-126 PMID: 29778506 PMCID: PMC6874212 SCOPUS ID: 2-s2.0-85047193308 05/21/2018 17 Citations

IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. (Choi J, Ye S, Eng KH, Korthauer K, Bradley WH, Rader JS, Kendziorski C) Stat Biosci 2017 Jun;9(1):1-12 PMID: 28966695 PMCID: PMC5617361 SCOPUS ID: 2-s2.0-84962297658 10/03/2017 1 Citation

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. (Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM) Gynecol Oncol 2017 Nov;147(2):283-290 PMID: 28802766 PMCID: PMC5704992 SCOPUS ID: 2-s2.0-85028062345 08/15/2017 51 Citations

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C) Gynecol Oncol 2017 Sep;146(3):477-483 PMID: 28756871 PMCID: PMC5570536 SCOPUS ID: 2-s2.0-85026308792 08/02/2017 59 Citations

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/gynecologic oncology group study (Von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G) Obstetrical and Gynecological Survey 1 August 2017;72(8):481-482 SCOPUS ID: 2-s2.0-85032301064 08/01/2017

Pediatric Gynecologic Cancers. (Pommert L, Bradley W) Curr Oncol Rep 2017 Jul;19(7):44 PMID: 28501984 SCOPUS ID: 2-s2.0-85019267655 05/16/2017 25 Citations

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. (Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G) Ann Oncol 2017 May 01;28(5):996-1004 PMID: 28453702 PMCID: PMC5406764 SCOPUS ID: 2-s2.0-85019984969 04/30/2017 79 Citations

Integrated genomic and molecular characterization of cervical cancer. (Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness &Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health &Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeir ão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine &Public Health, Van Andel Research Institute, Washington University in St Louis) Nature 2017 Mar 16;543(7645):378-384 PMID: 28112728 PMCID: PMC5354998 SCOPUS ID: 2-s2.0-85016138846 01/24/2017 1143 Citations

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. (von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G) Gynecol Oncol 2017 Mar;144(3):459-467 PMID: 28089376 PMCID: PMC5570471 SCOPUS ID: 2-s2.0-85009787702 01/17/2017 64 Citations

Endometrial carcinoma: The perioperative and long-term outcomes of robotic surgery in the morbidly obese. (Hinshaw SJ, Gunderson S, Eastwood D, Bradley WH) J Surg Oncol 2016 Dec;114(7):884-887 PMID: 27566529 SCOPUS ID: 2-s2.0-84983680299 10/30/2016 15 Citations

Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma. (Bradley WH, Eng K, Le M, Mackinnon AC, Kendziorski C, Rader JS) BMC Clin Pathol 2015;15:17 PMID: 26412982 PMCID: PMC4582729 SCOPUS ID: 2-s2.0-84942251757 09/29/2015 9 Citations

Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35 PMID: 26383827 PMCID: PMC4630152 SCOPUS ID: 2-s2.0-84952630402 09/19/2015 23 Citations

Pathway index models for construction of patient-specific risk profiles. (Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C) Stat Med 2013 Apr 30;32(9):1524-35 PMID: 23074142 PMCID: PMC3593986 SCOPUS ID: 2-s2.0-84876323512 10/18/2012 15 Citations

Recent advances in the surgical management of cervical cancer. (Zakashansky K, Bradley WH, Chuang L, Rahaman J, Dottino P) Mt Sinai J Med 2009 Dec;76(6):567-76 PMID: 20014423 SCOPUS ID: 2-s2.0-73349132009 12/17/2009 14 Citations

Pediatric Gynecologic Cancer (Bradley W, Rahaman J) Pediatric Adolescent Young Adult Gynecology 6 May 2009:390-396 SCOPUS ID: 2-s2.0-84891332750 05/06/2009

Patient clinical factors influencing use of hysterectomy in New York, 2001-2005 (Gretz H, Bradley WH, Zakashansky K, Nezhat F, Rahaman J, Chuang L, Bohren DL, Kreiger K, Rubin E, Sokolow A) Obstetrical and Gynecological Survey January 2009;64(1):22-23 SCOPUS ID: 2-s2.0-73449124095 01/01/2009 1 Citation

Patient clinical factors influencing use of hysterectomy in New York, 2001-2005. (Gretz H, Bradley WH, Zakashansky K, Nezhat F, Rahaman J, Chuang L, Bohren DL, Kreiger K, Rubin E, Sokolow A) Am J Obstet Gynecol 2008 Oct;199(4):349.e1-5 PMID: 18667172 SCOPUS ID: 2-s2.0-52949092373 08/01/2008 6 Citations

Effect of physician gender and specialty on utilization of hysterectomy in New York, 2001-2005. (Gretz H, Bradley WH, Zakashansky K, Nezhat F, Bohren DL, Kreiger K, Rubin E, Sokolow A) Am J Obstet Gynecol 2008 Oct;199(4):347.e1-6 PMID: 18639208 SCOPUS ID: 2-s2.0-52949135520 07/22/2008 9 Citations

Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. (Bradley WH, Dottino PR, Rahaman J) Int J Gynecol Cancer 2008;18(6):1364-7 PMID: 18217973 SCOPUS ID: 2-s2.0-40749152616 01/26/2008 15 Citations

New techniques in radical hysterectomy. (Zakashansky K, Bradley WH, Nezhat FR) Curr Opin Obstet Gynecol 2008 Feb;20(1):14-9 PMID: 18197000 SCOPUS ID: 2-s2.0-38149133845 01/17/2008 32 Citations

Robot-assisted laparoscopy (Bradley WH, Nezhat F) Nezhat S Operative Gynecologic Laparoscopy and Hysteroscopy 1 January 2008:577-581 SCOPUS ID: 2-s2.0-84928083293 01/01/2008 4 Citations

Endometrial carcinoma expresses an increased cathepsin B/D ratio. (Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS) Gynecol Oncol 2008 Jan;108(1):84-9 PMID: 17980407 SCOPUS ID: 2-s2.0-37449016836 11/06/2007 8 Citations

A multi-institutional review of outcomes of endometrial stromal sarcoma. (Leath CA 3rd, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH, Geller MA, Argenta PA, Gold MA) Gynecol Oncol 2007 Jun;105(3):630-4 PMID: 17320937 SCOPUS ID: 2-s2.0-34248386886 02/27/2007 181 Citations

Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. (Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP) Gynecol Oncol 2004 Dec;95(3):632-6 PMID: 15581975 SCOPUS ID: 2-s2.0-9944259988 12/08/2004 50 Citations

Hysteroscopy and cytology in endometrial cancer. (Bradley WH, Boente MP, Brooker D, Argenta PA, Downs LS, Judson PL, Carson LF) Obstet Gynecol 2004 Nov;104(5 Pt 1):1030-3 PMID: 15516397 SCOPUS ID: 2-s2.0-16244364003 11/02/2004 50 Citations

Last update: 05/05/2025

© 2025 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

William H. Bradley MD

Professor

Publications (63)